Active Recombinant Human CTSD, His-tagged
Cat.No. : | CTSD-1649H |
Product Overview : | Recombinant Human CTSD (Leu21-Leu412), fused with a C-terminal 10-His tag, was expressed in Mouse NSO Cells. |
- Specification
- Gene Information
- Related Products
Description : | This gene encodes a lysosomal aspartyl protease composed of a dimer of disulfide-linked heavy and light chains, both produced from a single protein precursor. This proteinase, which is a member of the peptidase C1 family, has a specificity similar to but narrower than that of pepsin A. Transcription of this gene is initiated from several sites, including one which is a start site for an estrogen-regulated transcript. Mutations in this gene are involved in the pathogenesis of several diseases, including breast cancer and possibly Alzheimer disease. |
Source : | Mammalian cells |
Species : | Human |
Tag : | His |
Predicted N Terminal : | Leu21 |
Form : | Supplied as a 0.2 µm filtered solution in MES and NaCl. |
Bio-activity : | Measured by its ability to cleave the fluorogenic peptide substrate, Mca-PLGL-Dpa-AR-NH2. |
Molecular Mass : | Predicted Molecular Mass: 44 kDaSDS-PAGE: 50 kDa, reducing conditions |
Endotoxin : | < 1.0 EU per 1 μg of the protein by the LAL method. |
Purity : | >95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Storage : | Avoid repeated freeze-thaw cycles.6 months from date of receipt, -20 to -70 °C as supplied.3 months, -20 to -70 °C under sterile conditions after opening. |
Reconstitution : | Reconstitute at 100 µg/mL in sterile, deionized water. |
Gene Name : | CTSD cathepsin D [ Homo sapiens (human) ] |
Official Symbol : | CTSD |
Synonyms : | CTSD; cathepsin D; CPSD; CLN10; MGC2311; cathepsin D; lysosomal aspartyl protease; lysosomal aspartyl peptidase; ceroid-lipofuscinosis, neuronal 10; Cathepsin D; EC 3.4.23.5; OTTHUMP00000042282; OTTHUMP00000196039; OTTHUMP00000198692 |
Gene ID : | 1509 |
mRNA Refseq : | NM_001909 |
Protein Refseq : | NP_001900 |
MIM : | 116840 |
UniProt ID : | P07339 |
Chromosome Location : | 11p15.5 |
Pathway : | Ceramide signaling pathway; Direct p53 effectors; LKB1 signaling events; Lysosome; Tuberculosis; thyroid hormone biosynthesis |
Function : | aspartic-type endopeptidase activity; peptidase activity |
Products Types
◆ Recombinant Protein | ||
CTSD-2752H | Recombinant Human CTSD Protein, His (Fc)-Avi-tagged | +Inquiry |
CTSD-2582H | Recombinant Human CTSD protein(71-410 aa), C-His-tagged | +Inquiry |
Ctsd-2369M | Recombinant Mouse Ctsd Protein, His-tagged | +Inquiry |
CTSD-786H | Recombinant Human CTSD Protein, His-tagged | +Inquiry |
CTSD-2103H | Recombinant Human CTSD Protein, GST-tagged | +Inquiry |
◆ Native Protein | ||
CTSD-27858TH | Native Human CTSD | +Inquiry |
CTSD-5325D | Active Native Human CTSD protein | +Inquiry |
CTSD-1648H | Active Native Human Cathepsin D | +Inquiry |
◆ Lysates | ||
CTSD-1735HCL | Recombinant Human CTSD cell lysate | +Inquiry |
CTSD-3023MCL | Recombinant Mouse CTSD cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-0264 | Cathepsin D Inhibitor Screening Kit | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionThere is an association between CTSD proteins and cognitive function. In some neurodegenerative diseases, abnormal accumulation and deposition of CTSD proteins may affect neuronal signaling and synaptic function, leading to a decline in cognitive function.
In some neurodegenerative diseases, levels of the CTSD protein may change. For example, people with Alzheimer's disease may have elevated levels of the CTSD protein. These changes may help in the diagnosis of the disease and in the assessment of the course of the disease.
For people with cognitive decline, their CTSD protein levels can be assessed by a blood or cerebrospinal fluid sample. This evaluation can help doctors understand whether the cause of cognitive decline is related to a neurodegenerative disease.
It is currently no treatment that directly targets the CTSD protein. However, some medications can reduce symptoms of neurodegenerative diseases, such as cholinesterase inhibitors such as donepezil, which can increase acetylcholine levels in synapses, which can improve cognitive function.
People with Parkinson's disease may have reduced levels of the CTSD protein. This decrease may be associated with neuronal death and impaired synaptic function. In addition, CTSD protein may also be associated with motor symptoms in patients with Parkinson's disease.
CTSD proteins play a role in Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. It may change in these diseases, leading to structural alterations and impaired signaling of neuronal synapses.
Customer Reviews (3)
Write a reviewGood at western-blot experiments.
In experiments, the biocompatibility performed well.
The experimental conditions are broad, and the experimental results are accurate and repeatable.
Ask a Question for All CTSD Products
Required fields are marked with *
My Review for All CTSD Products
Required fields are marked with *
Inquiry Basket